Skip to main content
Navigate Up
Sign In
 

Vasculitis Research Studies


​The Division of Rheumatology strives to understand more about vasculitis through research.  Please see the list below, which summarizes the studies available to individuals interested in advancing our understanding and treatment of rheumatic disease. 
 
​Study Name Brief Description​ Basic Eligibility​ Criteria Contact​
​SIRRESTA Use of an unapproved/ investigational protein (sirukumab). This study includes a placebo group. New onset Giant Cell / Temporal arteritis with high inflammatory marker (ESR>30, CRP >1mg/dL) ​​303-724-0581, 303-724-7518 or email karen.franklin@ucdenver.edu
​ADVOCATE ​Use of avacopan (medication approved to treat certain kidney disease) to treat vasculitis in comparison with rituximab or cyclophosphamide.  This study does not include a placebo group. Individuals with a ​positive blood test (ANCA).  303-724-0581, 303-724-7518 or email karen.franklin@ucdenver.edu
 
Please note that study status changes frequently and therefore, a listed study may not be actively enrolling. Also, the complete list of inclusion and exclusion criteria for a given study is often not listed due to its length.  A visit to determine an individuals eligibility may be required.  A placebo is an inactive substance or treatment that looks the same as, and is given the same way as, an active drug or treatment being tested. The effects of the active drug or treatment are compared to the effects of the placebo.